(1.天然药物活性物质与功能国家重点实验室 新药作用机制研究与药效学评价北京重点实验室 中国医学科学院 北京协和医学院药物研究所, 北京市 100050;2.浙江大学医学院附属杭州市第一人民医院药学部, 浙江省杭州市 310006;3.美国贝勒医学院医学部心血管研究室,德克萨斯州休斯顿市 77030;4.内蒙古医科大学基础医学院 药物筛选中心与新药安全评价和研究中心,内蒙古呼和浩特市 010110)
彭雪英,博士,药师,研究方向为脂质代谢与动脉粥样硬化,E-mail为pengxy1991@126.com。通信作者朱海波,博士,研究员,教授,研究方向为动脉粥样硬化相关疾病新药靶的发现和药物研发,E-mail为zhuhaibo@imm.ac.cn。
国家自然科学基金重大研究计划培育项目(91539126);中国医学科学院医学与健康科技创新工程重大协同创新项目(2016-I2M-1-009);国家科技重大专项-重大新药创制 (2018ZX09711001-003-011);国家自然科学基金青年科学基金项目(81703511)
PENG Xueying
State Key Laboratory for Bioactive Substances and Functions of Natural Medicines & Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study & Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China;Department of Clinical Pharmacy, Affiliated Hangzhou First Peoples Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, ChinaWANG Minjie
State Key Laboratory for Bioactive Substances and Functions of Natural Medicines & Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study & Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China;Center for Drug Screening and Center for New Drug Safety Evaluation and Research, School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010110, ChinaZHU Haibo
State Key Laboratory for Bioactive Substances and Functions of Natural Medicines & Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study & Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China1.State Key Laboratory for Bioactive Substances and Functions of Natural Medicines & Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study & Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China;2.Department of Clinical Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China;3.Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, United States;4.Center for Drug Screening and Center for New Drug Safety Evaluation and Research, School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010110, China)
彭雪英,武怀珠,王敏杰,朱海波.高脂血症、单核细胞亚型与动脉粥样硬化[J].中国动脉硬化杂志,2020,28(9):815~822.
复制